Access Update- #44
I had hoped that once I got off the boat I would no longer be dealing with the sickening up and down motion. But it seems as if I need my Sea-Calm just to come in to work every day.
It’s frustrating to see our stocks down, when there have been no fundamental changes in any of the companies. The important thing to remember is that we are waiting for catalysts on just about every name in the portfolio. Should these events, such as positive phase III data for Electro-Optical Sciences (Nasdaq: MELA) and Synta Pharmaceuticals (Nasdaq: SNTA), occur as we expect, a few points to the downside will be insignificant compared to the potential upside.
And keep in mind, we’re not playing these stocks simply for the one time events. We expect success to breed success. If the phase III data is strong, we should see FDA approval and significant sales in 2009. When SIGA Technologies (Nasdaq: SIGA) lands it’s $100 million government contract, we expect additional contracts to come its way.
I know it’s tough, but hang in there. These are great companies that have a lot going for them. If they hit the way we think they will, they could make up for some other parts of your portfolio that are not performing.
Earnings Season
A couple of our portfolio companies will be reporting quarterly results in the next few weeks. Here are the dates and what Wall Street is forecasting. I have also included fourth quarter and full year expectations so that you can compare any guidance figures to the current expectations. Of course, we’ll comment on the results as they become available.
ViroPharma (Nasdaq: VPHM)
Earnings Date: Wednesday, October 29th
Consensus Q3 EPS: $0.23
Consensus Q3 Revenue: $58.65M
Consensus Q4 EPS: $0.15
Consensus Q4 Revenue: $57.45M
Full Year 2008 EPS: $0.89
Full Year 2008 Revenue: $232.47M
Cytori Therapeutics (Nasdaq: CYTX)
Earnings Date: Friday, November 7th.
Consensus Q3 EPS: -$0.26
Consensus Q3 Revenue: $3.1M
Consensus Q4 EPS: $-0.20
Consensus Q4 Revenue: $4.93M
Full Year 2008 EPS: $-1.08
Full Year 2008 Revenue: $10.28M
SIGA Call Change
Our conference call with SIGA Technologies CEO Dr. Eric Rose has been pushed back a few days. The new date is now Wednesday, November 5th at 2:00 p.m. ET/1:00 p.m. CT/11:00 a.m. PT.
The dial in information is the same.
Dial in 5- 10 minutes before the start of the call.
Dial in #: 1-888-373-5705 or 1-719-457-384.
Passcode: 455882
Please submit any questions that you have for Dr. Rose to research@accessresearchgroup.com
Marc Lichtenfeld
Director of Research
Access Research Group
Current Portfolio:
Name: SIGA Technologies
Symbol: SIGA
Current Price:$2.91
Comments: Buy up to $4.00
Name: Synta Pharmaceuticals
Symbol: SNTA
Current Price: $6.00
Comments: Buy up to $13.00
Name: ViroPharma
Symbol: VPHM
Current Price: $10.56
Comments: Buy up to $12.50
Name: Cytori Therapeutics
Symbol: CYTX
Current Price: $3.30
Comments: Buy up to $8
Name: Electro-Optical Sciences
Symbol: MELA
Current Price: $2.57
Comments: Buy up to $5.75